CTLA4 and neoplasm: Nanovaccine with tumor antigen MUC1 mRNA designed against triple negative breast cancer in combination with an anti-CTLA-4 monoclonal antibody can be successfully delivered to DCs in lymph nodes resulting in an enhanced T cell anti-tumor immune response 61.